Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18590889 | 1.00 | PPARD (0.68) | PPARDTSHRLMNAALDH1A1HSD17B10 | |
| SCHEMBL9889143 | 1.00 | PPARD (0.68) | PPARDTSHRLMNAALDH1A1HSD17B10 | |
| SCHEMBL7451944 | 1.00 | PPARD (0.68) | PPARDTSHRLMNAALDH1A1HSD17B10 | |
| SCHEMBL30956301 | 1.00 | PPARD (0.68) | PPARDTSHRLMNAALDH1A1HSD17B10 | |
| SCHEMBL4456025 | 0.98 | PPARD (0.71) | PPARDTSHR | |
| SCHEMBL4158399 | 0.91 | PPARD (0.74) | PPARDTSHR | |
| SCHEMBL11323349 | 0.89 | PPARD (0.61) | PPARDTSHR | |
| SCHEMBL11514496 | 0.89 | PPARD (0.61) | PPARDTSHR | |
| SCHEMBL7268183 | 0.89 | PPARD (0.61) | PPARDTSHR | |
| SCHEMBL7268189 | 0.86 | PPARD (0.64) | PPARDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12019075-B2 | Zwitterionic nanoparticles | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) | 2024-06-25 | — | — | US | disclosed |
| US-20230160902-A1 | ZWITTERIONIC NANOPARTICLES | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230160902-A1 | ZWITTERIONIC NANOPARTICLES | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) | 2023-05-25 | — | — | US | disclosed |
| EP-3571263-B1 | USE OF ZWITTERIONIC NANOPARTICLES | FRAUNHOFER GES FORSCHUNG (DE) | 2022-03-30 | — | — | EP | disclosed |
| US-10471177-B2 | Surface modified biological materials | Orthobond Corporation (US) | 2019-11-12 | — | — | US | disclosed |
| US-20170266343-A1 | SURFACE MODIFIED BIOLOGICAL MATERIALS | ORTHOBOND, INC. | 2017-09-21 | — | — | US | disclosed |
| US-9655992-B2 | Surface modified biological materials | ORTHOBOND, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9139715-B2 | Coating of metal pigments using phosphonic acid-based compounds | SILBERLINE MANUFACTURING CO., INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-8846978-B2 | Electronic devices comprising novel phosphonic acid surface modifiers | IMPERIAL INNOVATIONS LTD. (GB) | 2014-09-30 | — | — | US | disclosed |
| US-8846978-B2 | Electronic devices comprising novel phosphonic acid surface modifiers | IMPERIAL INNOVATIONS LTD. (GB) | 2014-09-30 | — | — | US | disclosed |
| WO-2012149330-A1 | SURFACE MODIFIED BIOLOGICAL MATERIALS | ORTHOBOND, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120114974-A1 | ELECTRONIC DEVICES COMPRISING NOVEL PHOSPHONIC ACID SURFACE MODIFIERS | NATIONAL SCIENCE FOUNDATION | 2012-05-10 | — | — | US | disclosed |
| US-20120114974-A1 | ELECTRONIC DEVICES COMPRISING NOVEL PHOSPHONIC ACID SURFACE MODIFIERS | NATIONAL SCIENCE FOUNDATION | 2012-05-10 | — | — | US | disclosed |
| EP-2417142-A1 | ELECTRONIC DEVICES COMPRISING NOVEL PHOSPHONIC ACID SURFACE MODIFIERS | Georgia Tech Research Corporation (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115854-A1 | ELECTRONIC DEVICES COMPRISING NOVEL PHOSPHONIC ACID SURFACE MODIFIERS | GEORGIA TECH RESEARCH CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100051917-A1 | PRINTABLE THIN-FILM TRANSISTORS WITH HIGH DIELECTRIC CONSTANT GATE INSULATORS AND METHODS FOR PRODUCING SAME | NATIONAL SCIENCE FOUNDATION | 2010-03-04 | — | — | US | disclosed |
| US-20100027192-A1 | COATED METAL OXIDE NANOPARTICLES AND METHODS FOR PRODUCING SAME | GEORGIA TECH RESEARCH CORPORATION | 2010-02-04 | — | — | US | disclosed |
| WO-2008060534-A1 | PRINTABLE THIN-FILM TRANSISTORS WITH HIGH DIELECTRIC CONSTANT GATE INSULATORS AND METHODS FOR PRODUCING SAME | GEORGIA TECH RESEARCH CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-1888311-A2 | COATED METAL OXIDE NANOPARTICLES AND METHODS FOR PRODUCING SAME | GEORGIA TECH RESEARCH CORPORATION (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006124670-A2 | COATED METAL OXIDE NANOPARTICLES AND METHODS FOR PRODUCING SAME | GEORGIA TECH RESEARCH CORPORATION (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100027192-A1 | COATED METAL OXIDE NANOPARTICLES AND METHODS FOR PRODUCING SAME | NCL, PNN, NCDN | PPARD 4559/4885TSHR 1403/4885LMNA 843/4885 |
| US-12019075-B2 | Zwitterionic nanoparticles | ANXA3, ANXA5, ANXA11 | PPARD 4409/4885TSHR 3896/4885LMNA 2170/4885 |
| US-20230160902-A1 | ZWITTERIONIC NANOPARTICLES | ANXA3, ANXA5, ANXA11 | PPARD 4399/4885TSHR 3660/4885LMNA 1910/4885 |
| US-20120114974-A1 | ELECTRONIC DEVICES COMPRISING NOVEL PHOSPHONIC ACID SURFACE MODIFIERS | EFNA1, PHOSPHO1, EPHA6 | PPARD 2434/4885TSHR 4110/4885LMNA 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.